Not Signed In -
Warts |
Plantar Warts |
Clinical Trial: Twelve Week Safety and Efficacy Study with a Topical Gel to Treat Common Warts in Adults
This study is no longer recruiting patients.
|
Purpose
The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks.
A second purpose is to evaluate the safety of the drug.
| Condition | Intervention | Phase |
|---|---|---|
| Warts | Drug: Resiquimod | Phase II |
MedlinePlus related topics: Warts
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Single Blind, Dose Comparison, Single Group Assignment, Safety/Efficacy Study
Official Title: A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults
Secondary Outcomes: Partial clearance of treated common wart(s); Wart recurrence
Expected Total Enrollment: 88
Study start: March 2004; Study completion: March 2006
Last follow-up: September 2005; Data entry closure: October 2005
Eligibility
Inclusion Criteria:
- Diagnosis of common warts
- Two forms of birth control
Exclusion Criteria:
Location Information
Indiana
Welborn Clinic, Evansville, Indiana, 47713, United States
More Information
Record last reviewed: June 2005
Last Updated: June 30, 2005
Record first received: June 20, 2005
ClinicalTrials.gov Identifier: NCT00114920
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-07-05
email this page
print this page
bookmark this page
feedback on this page
